PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Key buying criteria PART 06: Antibacterial: Overview • Introduction • MOA • General principles for use of antibiotics • Clinical uses PART 07: Antimicrobial resistance • Sources of spread of resistant organisms • Initiatives to improve antibiotic innovation • Surveillance systems for antibiotic resistance PART 08: Legislation relating to antibiotics use in US PART 09: Pipeline analysis • Solithromycin • TD-1792 • Baxdela • Taksta PART 10: Market landscape • Global antibacterial drugs market • Global MRSA drugs market • Five forces analysis PART 11: Market segmentation by drug class • Tetracycline • Folate antagonists • Cephalosporin • Lipopeptide • Oxazolidinone • Lipoglycopeptide PART 12: Market segmentation by drug origin • Semisynthetic drugs • Synthetic drugs PART 13: Market segmentation by MOA • Bacteriostatic • Bactericidal PART 14: Geographical segmentation • Global MRSA drugs market by geographical segmentation 2015-2020 • MRSA drugs market in Americas • MRSA drugs market in EMEA • MRSA drugs market in APAC PART 15: Market drivers • Special regulatory designations • Increasing prevalence of infections • Growing awareness of diseases • Rise in older population PART 16: Impact of drivers PART 17: Market challenges • Development of drug-resistant strains • Patent expiries and generic penetration • Decreased investments in research activities PART 18: Impact of drivers and challenges PART 19: Market trends • Strategic alliances and M&A • Patient assistance programs • Increased funding for antibiotic research PART 20: Vendor landscape • Competitive scenario • Key vendor profiles • Allergan • Merck • Pfizer • Theravance • Other prominent vendors PART 21: Appendix • List of abbreviations PART 22: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Percentage of MRSA infections among Staphylococcus infections in US 2015 Exhibit 03: Percentage of MRSA infections in US based on type 2015 Exhibit 04: Sites of Staphylococcus infections Exhibit 05: Key buying criteria for MRSA drugs Exhibit 06: MOA of antibacterial drugs Exhibit 07: General principles involved in use of antibiotics Exhibit 08: Causes of AMR Exhibit 09: Sources of spread of resistant organisms Exhibit 10: Estimated deaths per year caused by AMR in 2050 Exhibit 11: Initiatives improving antibiotic innovation Exhibit 12: Surveillance systems of various countries Exhibit 13: Legislation relating to antibiotics use in US Exhibit 14: Pipeline portfolio: Global MRSA drugs market Exhibit 15: Global antibacterial drugs market 2015-2020 ($ billions) Exhibit 16: Market share of global MRSA drugs in global pharmaceutical market 2015 Exhibit 17: Global MRSA drugs market 2015-2020 ($ billions) Exhibit 18: Five forces analysis Exhibit 19: Cephalosporin segmentation by generation of drugs Exhibit 20: Global MRSA drugs market segmentation based on volume 2015 Exhibit 21: Global MRSA drugs market segmentation by drug origin Exhibit 22: Global MRSA drugs market segmentation by geography 2015 Exhibit 23: Global MRSA drugs market revenue by geography 2015-2020 ($ millions) Exhibit 24: Percentage share of global MRSA drugs market by geography 2015-2020 Exhibit 25: MRSA drugs market in Americas 2015-2020 ($ billions) Exhibit 26: Percentage share of MRSA drugs market in US 2015 Exhibit 27: MRSA drugs market in EMEA 2015-2020 ($ millions) Exhibit 28: MRSA drugs market in APAC 2015-2020 ($ millions) Exhibit 29: Global MRSA drugs market: YoY growth and revenue based on geography 2015-2020 Exhibit 30: Percentage of MRSA infections 2014 Exhibit 31: Impact of drivers Exhibit 32: Antibiotic-resistant strains of Staphylococcus according to period of development of resistance Exhibit 33: Ranking for top ten countries based on antibiotic consumption in livestock 2015 Exhibit 34: Antibacterial drug approvals by FDA and EMA Exhibit 35: Impact of drivers and challenges Exhibit 36: Allergan: Key takeaways Exhibit 37: Merck: YoY revenue and growth rate of Cubicin 2013-2015 ($ billion) Exhibit 38: Merck: Key takeaways Exhibit 39: Pfizer: YoY revenue and growth rate of Zyvox 2013-2015 ($ millions) Exhibit 40: Pfizer: YoY revenue and growth rate of Tygacil 2013-2015 ($ millions) Exhibit 41: Pfizer: Key takeaways Exhibit 42: Theravance Biopharma: YoY revenue comparison of Vibativ 2014-2015 ($ millions) Exhibit 43: Theravance: Key takeaways

Allergan, Merck, Pfizer, Theravance, Absynth Biologics, AmpliPhi Biosciences, AstraZeneca, Basilea Pharmaceutica , Baxter International, Cellceutix, Cempra, CrystalGenomics, Debiopharm, Galapagos NV, GSK, KYORIN Pharmaceutical, Lytix Biopharma, Melinta Therapeutics, Nabriva Therapeutics, NovaDigm Therapeutics, Paratek Pharmaceuticals, R-Pharm, Savara Pharmaceuticals, Sealife Pharma, Sequella, The Medicines Company, XBiotech.